Stock GNRO GENEURO SA
Add to a list
To use this feature you must be a member
Log inSign up

GeNeuro SA Stock

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:15 2024-05-31 am EDT 		5-day change 1st Jan Change
1.95 EUR +2.63% Intraday chart for GeNeuro SA +2.09% +78.90%
May. 16 GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 CI
Mar. 20 Geneuro SA Announces Appointments of Board of Directors CI

Financials

Sales 2024 * 28.2M 30.58M Sales 2025 * - Capitalization 57.71M 62.59M
Net income 2024 * 1M 1.08M Net income 2025 * -26M -28.2M EV / Sales 2024 * 2.33 x
Net Debt 2024 * 7.9M 8.57M Net Debt 2025 * 34.9M 37.85M EV / Sales 2025 * -
P/E ratio 2024 *
65 x
P/E ratio 2025 *
-2.24 x
Employees 17
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.25%
More Fundamentals * Assessed data

Chart GeNeuro SA

Dynamic Chart

Latest news about GeNeuro SA

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 CI
Geneuro SA Announces Appointments of Board of Directors CI
GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GeNeuro: share price falls after private placement CF
GeNeuro Raises EUR5 Million from Share Issue MT
GeNeuro appoints new Chief Medical Officer CF
Geneuro Sa Announces Executive Changes CI
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold CF
GeNeuro: positive opinion for continuation of trial CF
GeNeuro's Mid-stage Study for Post-COVID Symptoms Therapy Gets Medical Committee's Nod MT
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications CI
GeNeuro Finalizes Patient Enrollment in Early-stage Trial of Long-COVID Treatment MT
GeNeuro: end of recruitment for Covid long trial CF
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024 CI
GeNeuro and Verily Collaborate to Advance Long-COVID Research CI
More news

Press releases GeNeuro SA

Availability of documents and information for the annual shareholders’ meeting of June 12, 2024 BU
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024 BU
GeNeuro Publishes its 2024 Universal Registration Document BU
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update BU
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting BU
More press releases

News in other languages on GeNeuro SA

GeNeuro : Informations privilégiées / Autres communiqués
Modalités de mise à disposition des informations relatives à l’assemblée générale des actionnaires du 12 juin 2024
Le plafond boursier a sauté
En Direct des Marchés : Vallourec, Ubisoft, Cisco, Euronext, Netflix, Siemens, Chubb...
GeNeuro annonce la dernière visite du dernier patient dans son étude post-COVID et confirme que les principaux résultats seront disponibles à fin juin 2024
More news

Quotes and Performance

1 day+2.63%
1 week+2.09%
1 month+33.56%
3 months+52.94%
6 months+89.32%
Current year+78.90%
More quotes

Highs and lows

1 week
1.78
Extreme 1.78
1.98
1 month
1.42
Extreme 1.42
2.10
Current year
1.05
Extreme 1.05
2.10
1 year
0.94
Extreme 0.94
2.10
3 years
0.94
Extreme 0.94
4.39
5 years
0.94
Extreme 0.94
6.28
10 years
0.94
Extreme 0.94
13.72
More quotes

Managers and Directors - GeNeuro SA

Managers TitleAgeSince
Jesús Martin-Garcia CEO
 Chief Executive Officer 62 05-12-31
Hervé Perron FOU
 Founder 66 05-12-31
Miguel Payró DFI
 Director of Finance/CFO 62 15-10-31
Members of the board TitleAgeSince
Philippe Archinard BRD
 Director/Board Member 63 21-05-26
Michel Dubois BRD
 Director/Board Member 81 08-07-15
Gordon Francis BRD
 Director/Board Member 75 15-03-16
More insiders

Quotes

Date Price Change Volume
24-05-31 1.95 +2.63% 13,796
24-05-30 1.9 -0.26% 16,590
24-05-29 1.905 -1.80% 9,053
24-05-28 1.94 +0.52% 2,499
24-05-27 1.93 +1.05% 228

Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT

More quotes

Company Profile

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Sector
Biotechnology & Medical Research
Calendar
2024-06-12 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.95 EUR
Average target price
4 EUR
Spread / Average Target
+105.13%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENEURO SA Stock GeNeuro SA
+78.90% 62.59M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNRO Stock